Mallet Amélie, Ombline De Calbiac, Robert Marie, Campone Mario, Frenel Jean Sébastien
Département d'oncologie médicale, Institut de cancérologie de l'Ouest - René Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France.
Département d'oncologie médicale, Institut de cancérologie de l'Ouest - René Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France.
Bull Cancer. 2021 Dec;108(11S):11S19-11S25. doi: 10.1016/S0007-4551(21)00633-0.
The emergence of a new tumor entity called HER2-low breast cancer leads us to reconsider therapeutic indications in patients whose tumors were usually considered as luminal or triple negative. The development of antibody-drug conjugates (ADCs) allows using HER2 as a vector of a cytoxic drug with significant clinical efficacy in breast cancer with low HER2 expression. Trastuzumab deruxtecan monotherapy is currently evaluated in phase III trials in HER2-low patients, but also in combination in earlier phase studies. Many ADCs are in development, with highly anticipated results. The toxicities of these various ADCs seem manageable and compatible with prolonged administration. Her2-low breast cancer subtype may benefit from dedicated therapeutic strategies in the next few years.
一种名为HER2低表达乳腺癌的新肿瘤实体的出现，促使我们重新思考那些肿瘤通常被认为是管腔型或三阴性患者的治疗指征。抗体药物偶联物（ADC）的发展使得HER2可作为一种细胞毒性药物的载体，在HER2低表达的乳腺癌中具有显著的临床疗效。曲妥珠单抗德瓦鲁单抗单药治疗目前正在HER2低表达患者中进行III期试验评估，同时也在早期阶段研究中进行联合治疗评估。许多ADC正在研发中，结果备受期待。这些不同ADC的毒性似乎可控，且与长期给药相容。HER2低表达乳腺癌亚型在未来几年可能会受益于专门的治疗策略。
